Latest News for: mc4r

Edit

Superluminal Medicines Announces a Selective, Biased, MC4R Agonist is Advancing to IND-enabling Studies for the Treatment of Obesity

PR Newswire 22 Jul 2025
Superluminal's compound is an orally administered, highly selective, biased MC4R agonist initially targeting rare genetic forms of obesity and hypothalamic obesity, with potential as a treatment for general obesity in combination with GLP-1 drugs.
Edit

Congruence Therapeutics Announces Oral Presentation on MC4R Corrector Development Candidate CGX-926 for Early-Onset Obesity at ...

Citizen Tribune 16 Jul 2025
MONTREAL, July 16, 2025 /PRNewswire/ -- Congruence Therapeutics, a ...
Edit

Congruence Therapeutics Announces Oral Presentation on MC4R Corrector Development Candidate CGX-926 for Early-Onset Obesity at the 3rd Annual Obesity & Weight Loss Drug Development Summit

PR Newswire 16 Jul 2025
"Mutations of the MC4R gene, leading to protein misfolding and impaired trafficking, are the leading cause of severe early-onset genetic obesity," commented Sharath Hegde, Ph.D., Chief Scientific Officer of Congruence.
Edit

Palatin Announces Positive Preclinical Efficacy Data for Oral MC4R Agonist PL7737 in Animal Model of Obesity (Palatin Technologies Inc)

Public Technologies 15 Jul 2025
). The text version of this document is not available ... Disclaimer ... (noodl. 125377829) .
Edit

Palatin Announces Positive Preclinical Efficacy Data for Oral MC4R Agonist PL7737 in Animal Model of Obesity

PR Newswire 15 Jul 2025
Spana continued, "Palatin is developing a strong pipeline of novel MC4R agonists to treat obesity. Unlike incretin-based therapies, MC4R agonists offer a unique mechanism of action ... PL7737, an MC4R ...
Edit

Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025

Enid News & Eagle 13 Jul 2025
- Presentations highlight clinically meaningful reductions in BMI in patients with acquired hypothalamic obesity – ... .
Edit

Rhythm Pharmaceuticals Announces Oral MC4R Agonist Bivamelagon Achieved Statistically Significant, Clinically Meaningful BMI Reductions in ...

Nasdaq Globe Newswire 09 Jul 2025
-- Bivamelagon achieved BMI reductions in patients with acquired ...
Edit

Rhythm Pharmaceuticals Announces Oral MC4R Agonist Bivamelagon Achieved Statistically Significant, Clinically Meaningful BMI Reductions in Placebo-controlled Phase 2 Trial in Acquired Hypothalamic Obesity (Form 8-K) (Rhythm Pharmaceuticals Inc)

Public Technologies 09 Jul 2025
Rhythm Pharmaceuticals Announces Oral MC4R Agonist Bivamelagon Achieved Statistically Significant, Clinically Meaningful BMI Reductions in Placebo-controlled Phase 2 Trial in Acquired Hypothalamic Obesity.
Edit

Rhythm Pharmaceuticals To Announce Topline Results from Phase 2 Trial Evaluating Oral MC4R

Enid News & Eagle 08 Jul 2025
(Nasdaq.
Edit

Rhythm Pharmaceuticals To Announce Topline Results from Phase 2 Trial Evaluating Oral MC4R Agonist Bivamelagon ...

Nasdaq Globe Newswire 08 Jul 2025
... an investigational oral melanocortin-4 receptor (MC4R) agonist, in patients with acquired hypothalamic obesity.
  • 1

Article Search

tools
×
×
×
×